Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of allogeneic mesenchymal stem cells for extensive chronic graft-versus-host disease
ChiCTR-TRC-09000536Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2009
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MSV alogénicas in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Remission rate and Safety of MSC treatment. Started Sep 2009; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ChiCTR-TRC-09000536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000536.